<?xml version='1.0' encoding='utf-8'?>
<document id="28449367"><sentence text="Metoprolol-pridopidine drug-drug interaction and food effect assessments of pridopidine, a new drug for treatment of Huntington's disease."><entity charOffset="0-10" id="DDI-PubMed.28449367.s1.e0" text="Metoprolol" /><entity charOffset="76-87" id="DDI-PubMed.28449367.s1.e1" text="pridopidine" /><pair ddi="false" e1="DDI-PubMed.28449367.s1.e0" e2="DDI-PubMed.28449367.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28449367.s1.e0" e2="DDI-PubMed.28449367.s1.e1" /></sentence><sentence text="Pridopidine is an oral drug in clinical development for treatment of patients with Huntington's disease"><entity charOffset="0-11" id="DDI-PubMed.28449367.s2.e0" text="Pridopidine" /></sentence><sentence text=" This study examined the interactions of pridopidine with in vitro cytochrome P450 activity and characterized the effects of pridopidine on CYP2D6 activity in healthy volunteers using metoprolol as a probe substrate"><entity charOffset="41-52" id="DDI-PubMed.28449367.s3.e0" text="pridopidine" /><entity charOffset="125-136" id="DDI-PubMed.28449367.s3.e1" text="pridopidine" /><entity charOffset="184-194" id="DDI-PubMed.28449367.s3.e2" text="metoprolol" /><pair ddi="false" e1="DDI-PubMed.28449367.s3.e0" e2="DDI-PubMed.28449367.s3.e0" /><pair ddi="false" e1="DDI-PubMed.28449367.s3.e0" e2="DDI-PubMed.28449367.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28449367.s3.e0" e2="DDI-PubMed.28449367.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28449367.s3.e1" e2="DDI-PubMed.28449367.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28449367.s3.e1" e2="DDI-PubMed.28449367.s3.e2" /></sentence><sentence text=" The effect of food on pridopidine exposure was assessed"><entity charOffset="23-34" id="DDI-PubMed.28449367.s4.e0" text="pridopidine" /></sentence><sentence text="" /><sentence text="The ability of pridopidine to inhibit and/or induce in vitro activity of drug metabolizing enzymes was examined in human liver microsomes and fresh hepatocytes"><entity charOffset="15-26" id="DDI-PubMed.28449367.s6.e0" text="pridopidine" /></sentence><sentence text=" CYP2D6 inhibition potency and reversibility was assessed using dextromethorphan"><entity charOffset="64-80" id="DDI-PubMed.28449367.s7.e0" text="dextromethorphan" /></sentence><sentence text=" For the clinical assessment, 22 healthy subjects were given metoprolol 100 mg alone and concomitantly with steady-state pridopidine 45 mg twice daily"><entity charOffset="61-71" id="DDI-PubMed.28449367.s8.e0" text="metoprolol" /><entity charOffset="121-132" id="DDI-PubMed.28449367.s8.e1" text="pridopidine" /><pair ddi="false" e1="DDI-PubMed.28449367.s8.e0" e2="DDI-PubMed.28449367.s8.e0" /><pair ddi="false" e1="DDI-PubMed.28449367.s8.e0" e2="DDI-PubMed.28449367.s8.e1" /></sentence><sentence text=" Food effect on a single 90 mg dose of pridopidine was evaluated in a crossover manner"><entity charOffset="39-50" id="DDI-PubMed.28449367.s9.e0" text="pridopidine" /></sentence><sentence text=" Safety assessments and pharmacokinetic sampling occurred throughout the study" /><sentence text="" /><sentence text="Pridopidine was found to be a metabolism dependent inhibitor of CYP2D6, the main enzyme catalysing its own metabolism"><entity charOffset="0-11" id="DDI-PubMed.28449367.s12.e0" text="Pridopidine" /></sentence><sentence text=" Flavin-containing monooxygenase heat inactivation of liver microsomes did not affect pridopidine metabolism-dependent inhibition of CYP2D6 and its inhibition of CYP2D6 was not reversible with addition of FeCN3 "><entity charOffset="1-7" id="DDI-PubMed.28449367.s13.e0" text="Flavin" /><entity charOffset="86-97" id="DDI-PubMed.28449367.s13.e1" text="pridopidine" /><pair ddi="false" e1="DDI-PubMed.28449367.s13.e0" e2="DDI-PubMed.28449367.s13.e0" /><pair ddi="false" e1="DDI-PubMed.28449367.s13.e0" e2="DDI-PubMed.28449367.s13.e1" /></sentence><sentence text=" Exposure to metoprolol was markedly increased when coadministered with pridopidine; the ratio of the geometric means (90% confidence interval) for maximum observed plasma concentration, and area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration and extrapolated to infinity were 3"><entity charOffset="13-23" id="DDI-PubMed.28449367.s14.e0" text="metoprolol" /><entity charOffset="72-83" id="DDI-PubMed.28449367.s14.e1" text="pridopidine" /><pair ddi="false" e1="DDI-PubMed.28449367.s14.e0" e2="DDI-PubMed.28449367.s14.e0" /><pair ddi="false" e1="DDI-PubMed.28449367.s14.e0" e2="DDI-PubMed.28449367.s14.e1" /></sentence><sentence text="5 (2" /><sentence text="9, 4" /><sentence text="22), 6" /><sentence text="64 (5" /><sentence text="27, 8" /><sentence text="38) and 6" /><sentence text="55 (5" /><sentence text="18, 8" /><sentence text="28), respectively" /><sentence text=" Systemic exposure to pridopidine was unaffected by food conditions"><entity charOffset="22-33" id="DDI-PubMed.28449367.s24.e0" text="pridopidine" /></sentence><sentence text="" /><sentence text="As pridopidine is a metabolism-dependent inhibitor of CYP2D6, systemic levels of drugs metabolized by CYP2D6 may increase with chronic coadministration of pridopidine"><entity charOffset="3-14" id="DDI-PubMed.28449367.s26.e0" text="pridopidine" /><entity charOffset="155-166" id="DDI-PubMed.28449367.s26.e1" text="pridopidine" /><pair ddi="false" e1="DDI-PubMed.28449367.s26.e0" e2="DDI-PubMed.28449367.s26.e0" /><pair ddi="false" e1="DDI-PubMed.28449367.s26.e0" e2="DDI-PubMed.28449367.s26.e1" /></sentence><sentence text=" Pridopidine can be administered without regard to food"><entity charOffset="1-12" id="DDI-PubMed.28449367.s27.e0" text="Pridopidine" /></sentence><sentence text="" /></document>